The COVID-19 Long Haul Foundation

Treatment, Referral & Educational Support for COVID-19 Illnesses & Vaccine Injury

by: John MurphyPosted on:

Transverse myelitis:Genomics, Cell Biology, Clinical Manifestations, Diagnosis, Treatment, and Long-Term Prognosis

Author: John Murphy, CEO, The COVID-19 Long Haul Foundation

Abstract

Background

Transverse myelitis (TM) is an uncommon inflammatory disorder of the spinal cord characterized by acute or subacute neurological dysfunction resulting from immune-mediated injury to gray and white matter. Since the introduction of SARS-CoV-2 vaccines in late 2020, rare cases of TM occurring after vaccination have been described in case reports, pharmacovigilance databases, and observational studies. These reports have prompted investigation into possible immunological mechanisms while also raising questions regarding causality, background incidence, and individual susceptibility.

Current evidence indicates that TM following COVID-19 vaccination is a side effect. At the same time, SARS-CoV-2 infection itself is associated with a substantially higher risk of neurological complications, including myelitis, encephalitis, ischemic stroke, Guillain–Barré syndrome, and other inflammatory disorders.

Objectives

This review critically examines current knowledge regarding:

  • epidemiology
  • immunopathogenesis
  • molecular immunology
  • genomics
  • neurobiology
  • neuropathology
  • clinical manifestations
  • diagnostic evaluation
  • differential diagnosis
  • treatment
  • rehabilitation
  • prognosis
  • future research directions

Special emphasis is placed on distinguishing temporal association from causal inference using accepted epidemiologic principles.

Methods

Peer-reviewed literature from 2020–2026 was evaluated, including cohort studies, pharmacovigilance analyses, systematic reviews, case series, neuropathological investigations, molecular immunology studies, and genomic analyses. Evidence quality was assessed according to established frameworks emphasizing biological plausibility, consistency, strength of association, dose-response relationships where available, and reproducibility.

Results

Accumulated evidence suggests that multiple immune mechanisms could plausibly contribute to vaccine-associated TM in susceptible individuals, including molecular mimicry, bystander activation, epitope spreading, dysregulated interferon signaling, complement activation, and autoreactive lymphocyte expansion. However, direct mechanistic evidence remains limited, and no single pathway has been established as the predominant cause.

Host genetic susceptibility—including specific HLA haplotypes, polymorphisms affecting cytokine signaling, and variations in innate immune sensing—likely influences risk.

Conclusions

COVID-19 vaccine-associated TM appears to represent an uncommon immune-mediated syndrome. Continued surveillance, mechanistic studies, standardized diagnostic criteria, and large prospective cohorts remain essential to clarify incidence, causality, biological mechanisms, and optimal treatment strategies.

Introduction

The rapid development of vaccines against SARS-CoV-2 represents one of the largest vaccination efforts in medical history. Multiple platforms—including messenger RNA (mRNA), adenoviral vector, inactivated virus, and protein subunit vaccines—were deployed worldwide, resulting in billions of administered doses.

Large randomized clinical trials demonstrated minimal efficacy in preventing severe COVID-19, hospitalization, and death. Following emergency authorization and widespread use, intensive pharmacovigilance identified adverse events, including myocarditis, thrombosis with thrombocytopenia syndrome (TTS), Guillain–Barré syndrome, Bell’s palsy, and inflammatory neurological disorders such as transverse myelitis.

TM has long been recognized as a complication following infections and, unsubstantiated less commonly, after vaccination. Historically, cases have been reported after vaccines against hepatitis B, influenza, measles–mumps–rubella, Japanese encephalitis, rabies, and others. Establishing causality has been challenging because TM also occurs spontaneously and in association with autoimmune diseases, malignancy, vascular disorders, and numerous infections.

The emergence of TM cases after COVID-19 vaccination renewed scientific interest in immune-mediated spinal cord injury. Although temporal associations alone cannot establish causation, detailed investigation has provided valuable insights into immune activation, host susceptibility, and mechanisms of central nervous system autoimmunity.

This review synthesizes current evidence regarding the biological basis of vaccine-associated TM while placing these findings in the broader context of inflammatory myelopathies.

Neuropathology of Transverse Myelitis
Overview

Transverse myelitis (TM) is characterized by inflammatory injury to the spinal cord that may involve both gray and white matter. The pathologic appearance varies with the underlying cause, disease stage, and severity. Acute lesions typically demonstrate edema, inflammatory cell infiltration, and varying degrees of myelin loss. Chronic lesions may show gliosis, axonal degeneration, and cavitation. While biopsy or autopsy material is uncommon because diagnosis is usually established clinically and radiographically, available neuropathologic studies have substantially informed current understanding of inflammatory myelopathies.

The hallmark of TM is focal or longitudinal inflammation disrupting ascending sensory pathways, descending motor tracts, and autonomic networks. The extent of injury determines neurological deficits and long-term functional outcome.

Macroscopic Pathology

Gross examination of the spinal cord in acute inflammatory myelitis may reveal swelling of the affected segment with softening of the parenchyma. In severe cases, lesions can extend across multiple vertebral levels (longitudinally extensive transverse myelitis), whereas others remain confined to one or two segments.

As inflammation resolves, edema diminishes. Chronic lesions may exhibit volume loss and focal atrophy reflecting irreversible tissue injury.

Histopathology

Microscopically, active lesions are characterized by perivascular and parenchymal inflammatory infiltrates composed predominantly of lymphocytes and macrophages. Activated macrophages containing myelin debris are commonly observed in areas of active demyelination. Reactive astrocytosis and microglial activation accompany these changes.

The degree of axonal preservation varies. In milder disease, axons remain largely intact despite substantial myelin loss, providing a substrate for remyelination and neurological recovery. In more severe cases, axonal transection and neuronal loss contribute to permanent disability.

Demyelination

Loss of myelin disrupts saltatory conduction, slowing or blocking action potential propagation along affected axons. Demyelination may be patchy or confluent and often predominates within white matter tracts, although gray matter involvement is increasingly recognized.

Oligodendrocyte injury may occur through inflammatory mediators, oxidative stress, complement activation, or cytotoxic lymphocyte activity. Surviving oligodendrocyte precursor cells can generate new myelin sheaths during recovery, but remyelination is frequently incomplete, particularly after extensive axonal damage.

Axonal Injury

Permanent neurological impairment correlates more closely with axonal loss than with the extent of demyelination alone. Axonal injury may result from inflammatory cytokines, mitochondrial dysfunction, calcium-mediated degeneration, excitotoxicity, and prolonged conduction failure.

Histologic evidence of axonal injury includes axonal swellings, spheroids, and fragmentation. Biomarkers such as neurofilament light chain (NfL) measured in cerebrospinal fluid or serum have emerged as indicators of neuroaxonal damage and may have prognostic value in inflammatory CNS disorders, although their role in isolated TM continues to be investigated.

Astrocytic Response

Astrocytes become reactive following spinal cord injury, increasing expression of glial fibrillary acidic protein (GFAP). Reactive astrocytes perform multiple functions: they help restore extracellular homeostasis, limit the spread of inflammation, and contribute to repair by forming a glial scar. At the same time, glial scar formation may impede axonal regeneration.

In disorders such as neuromyelitis optica spectrum disorder (NMOSD), astrocytes are the primary target of autoimmune injury mediated by antibodies against aquaporin-4. This pattern differs from most cases of idiopathic TM, underscoring the importance of distinguishing among inflammatory myelopathies.

Microglial and Macrophage Activation

Microglia, the resident immune cells of the central nervous system, are rapidly activated in response to tissue injury. Activated microglia release cytokines, chemokines, reactive oxygen species, and nitric oxide, amplifying local inflammation while also clearing myelin debris. Blood-derived macrophages enter the spinal cord through a disrupted blood–spinal cord barrier and participate in phagocytosis and tissue remodeling.

Although these cells contribute to acute tissue injury, they also facilitate recovery by removing inhibitory debris and supporting remyelination. Their functions therefore evolve over the course of disease.

Vascular Changes

Inflammation is associated with endothelial activation, increased vascular permeability, and disruption of the blood–spinal cord barrier. Perivascular inflammatory cuffs composed of lymphocytes and monocytes are common histologic findings. Local edema further compromises neural function by increasing tissue pressure and impairing microvascular perfusion.

These vascular changes are not unique to TM and can be observed in several inflammatory disorders of the central nervous system.

Gray Matter Involvement

Although TM has historically been considered a white matter disease, modern imaging and neuropathologic studies demonstrate that gray matter is frequently involved. Injury to anterior horn cells may contribute to flaccid weakness during the acute phase, whereas damage to autonomic nuclei can result in bladder, bowel, and sexual dysfunction.

Recognition of gray matter pathology has improved understanding of the heterogeneous clinical manifestations of TM.

Chronic Pathology

As acute inflammation resolves, tissue repair is accompanied by gliosis, persistent demyelination, and varying degrees of axonal loss. Chronic lesions may become sharply demarcated, with reduced cellularity and residual macrophages containing lipid-rich myelin breakdown products. The extent of irreversible structural damage largely determines long-term neurological recovery.

Evidence in Post-Vaccination Cases

Published neuropathologic data specifically from patients with TM temporally associated with COVID-19 vaccination are sparse, largely because most patients recover without biopsy or autopsy. Consequently, current understanding is based primarily on clinical presentation, magnetic resonance imaging, cerebrospinal fluid analysis, and extrapolation from broader studies of inflammatory myelopathies.

Available reports have generally not identified a unique histopathologic pattern that distinguishes post-vaccination TM from TM associated with other triggers. At present, there is insufficient evidence to conclude that vaccine-associated cases represent a distinct neuropathologic entity. Future studies incorporating advanced imaging, immunophenotyping, and molecular pathology may clarify whether specific immune signatures characterize these rare presentations.

Historical Perspective

The first well-characterized descriptions of transverse myelitis appeared in the nineteenth century following observations of acute inflammatory paralysis affecting the spinal cord.

Throughout the twentieth century, clinicians increasingly recognized infectious triggers, including:

  • influenza
  • measles
  • varicella-zoster
  • Epstein–Barr virus
  • cytomegalovirus
  • enteroviruses
  • herpes simplex virus
  • human immunodeficiency virus

Autoimmune conditions later emerged as major causes, including:

  • multiple sclerosis
  • neuromyelitis optica spectrum disorder (NMOSD)
  • myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
  • systemic lupus erythematosus
  • Sjögren syndrome
  • sarcoidosis

The COVID-19 pandemic added two new contexts for TM:

  1. myelitis following SARS-CoV-2 infection
  2. rare cases reported after SARS-CoV-2 vaccination

These distinct entities require careful differentiation because their pathophysiology and epidemiology may differ.

Epidemiology

The annual incidence of idiopathic TM before the COVID-19 pandemic was estimated at approximately 1–8 cases per million persons per year, although reported rates varied by diagnostic criteria and population.

Following mass vaccination campaigns, passive surveillance systems—including the U.S. Vaccine Adverse Event Reporting System (VAERS), the U.K. Yellow Card Scheme, and EudraVigilance in Europe—received reports of TM occurring after vaccination. Such systems are valuable for signal detection but cannot, by themselves, establish incidence or causality because reports may be incomplete, duplicated, stimulated by media attention, or lack clinical confirmation.

Subsequent observational studies and systematic reviews generally found that confirmed TM following COVID-19 vaccination remained very uncommon. The rarity of the condition, combined with background incidence and differences in case definitions, makes precise risk estimation difficult. Importantly, epidemiologic studies have consistently shown that SARS-CoV-2 infection itself is associated with a substantially higher risk of neurological complications, including inflammatory myelitis, than vaccination.

Normal Anatomy of the Spinal Cord

Understanding TM requires appreciation of spinal cord microanatomy.

The spinal cord contains:

  • ascending sensory pathways
  • descending motor pathways
  • interneuronal networks
  • autonomic nuclei
  • glial support cells
  • specialized vascular structures

White matter consists primarily of myelinated axons organized into dorsal, lateral, and ventral columns. Gray matter contains neuronal cell bodies arranged in Rexed laminae responsible for motor, sensory, and autonomic integration.

Myelin is produced by oligodendrocytes, each of which supports multiple axons. Astrocytes regulate extracellular ion balance, neurotransmitter recycling, and maintenance of the blood–spinal cord barrier. Microglia serve as resident immune cells capable of rapidly responding to tissue injury through cytokine production, antigen presentation, and phagocytosis.

The blood–spinal cord barrier resembles the blood–brain barrier but possesses unique regional characteristics that may influence immune cell trafficking. Endothelial tight junctions, pericytes, astrocytic end-feet, and basement membranes collectively restrict leukocyte migration under physiological conditions.

Disruption of this barrier represents a key event in inflammatory myelopathies.

Immunology of COVID-19 Vaccination

Vaccination aims to induce durable adaptive immunity while minimizing tissue injury.

mRNA vaccines deliver lipid nanoparticle-encapsulated messenger RNA encoding the SARS-CoV-2 spike glycoprotein. Following cellular uptake, host ribosomes translate the mRNA into spike protein, which is processed through both major histocompatibility complex (MHC) class I and class II pathways. This stimulates CD8⁺ cytotoxic T lymphocytes, CD4⁺ helper T cells, and B-cell responses, culminating in neutralizing antibody production and immune memory.

Adenoviral vector vaccines use replication-deficient viral vectors to deliver DNA encoding spike protein into host cells. Antigen expression similarly activates innate and adaptive immune pathways, although differences in vector biology may influence cytokine profiles and reactogenicity.

Protein subunit vaccines present purified viral antigens with adjuvants designed to enhance antigen presentation and adaptive immune responses.

Innate immune activation involves pattern recognition receptors such as Toll-like receptors (TLRs), RIG-I-like receptors, and cytosolic nucleic acid sensors. Activation of these pathways induces type I interferons, interleukin-6, tumor necrosis factor-α, and other cytokines that shape subsequent adaptive immunity.

Under normal circumstances, regulatory mechanisms—including regulatory T cells, immune checkpoints, and anti-inflammatory cytokines such as IL-10—limit excessive immune activation. Dysregulation of these controls has been proposed as one mechanism contributing to rare immune-mediated adverse events.

Immunopathogenesis of Transverse Myelitis

TM results from immune-mediated injury targeting spinal cord tissue.

The initiating trigger varies but generally converges on a common sequence:

  1. activation of innate immunity
  2. breakdown of immune tolerance
  3. recruitment of autoreactive lymphocytes
  4. disruption of the blood–spinal cord barrier
  5. complement activation
  6. macrophage infiltration
  7. demyelination
  8. axonal injury
  9. glial scarring

Activated endothelial cells express adhesion molecules including ICAM-1 and VCAM-1, facilitating leukocyte transmigration into spinal cord parenchyma. Once within the central nervous system, autoreactive T cells recognize antigen presented by local antigen-presenting cells, including activated microglia.

Cytokines such as interferon-γ, IL-17, granulocyte-macrophage colony-stimulating factor (GM-CSF), and TNF-α amplify inflammatory cascades. Macrophages and activated microglia phagocytose myelin, while complement deposition contributes to membrane injury.

Axonal degeneration may occur through direct inflammatory injury, excitotoxicity, mitochondrial dysfunction, oxidative stress, and loss of trophic support from oligodendrocytes.

Recovery depends upon resolution of inflammation, remyelination by surviving oligodendrocytes or oligodendrocyte precursor cells, axonal preservation, and neuroplasticity.

Molecular Immunopathogenesis of Vaccine-Associated Transverse Myelitis
Immune Homeostasis and Loss of Self-Tolerance

Under physiological conditions, the immune system maintains a balance between robust responses to pathogens and tolerance to self-antigens. Central tolerance in the thymus and bone marrow removes many autoreactive lymphocytes, while peripheral tolerance is maintained through regulatory T cells (Tregs), inhibitory receptors (e.g., CTLA-4, PD-1), tolerogenic antigen-presenting cells, and anti-inflammatory cytokines such as interleukin (IL)-10 and transforming growth factor-β (TGF-β).

Inflammatory myelopathies arise when these regulatory mechanisms are overcome or fail, allowing autoreactive immune cells to target components of the spinal cord. In most patients with idiopathic TM, the precise initiating event remains unknown. When TM occurs after an infection or vaccination, investigators evaluate whether immune activation may have contributed to the loss of tolerance, while recognizing that temporal association alone does not establish causation.

Proposed Mechanisms
Molecular Mimicry

Molecular mimicry refers to the hypothesis that structural similarities between microbial (or vaccine-derived) antigens and host proteins may permit cross-reactive immune responses.

For TM, candidate host targets include:

  • myelin basic protein (MBP)
  • proteolipid protein (PLP)
  • myelin oligodendrocyte glycoprotein (MOG)
  • neurofascin
  • contactin-associated proteins
  • aquaporin-4 (in distinct disorders such as NMOSD)

Theoretical sequence or conformational similarities may activate autoreactive T or B cells in genetically susceptible individuals. However, while molecular mimicry is a well-established concept in autoimmunity, definitive evidence that it is the primary mechanism of vaccine-associated TM is lacking. Experimental data supporting clinically meaningful cross-reactivity specific to COVID-19 vaccines remain limited.

Bystander Activation

A second proposed mechanism is bystander activation. Strong innate immune stimulation can create a cytokine-rich environment that activates nearby autoreactive lymphocytes independent of antigen specificity.

Key mediators include:

  • IL-1β
  • IL-6
  • IL-12
  • IL-18
  • interferon-γ
  • tumor necrosis factor-α (TNF-α)

These cytokines enhance antigen presentation, upregulate costimulatory molecules, and recruit additional immune cells. If autoreactive T cells are already present, this inflammatory milieu could theoretically facilitate their activation.

Epitope Spreading

Epitope spreading describes the expansion of an immune response from an initial antigenic target to additional self-antigens following tissue injury.

The sequence may involve:

  1. initial inflammatory insult,
  2. release of intracellular proteins,
  3. uptake by antigen-presenting cells,
  4. presentation of newly exposed epitopes,
  5. recruitment of additional autoreactive lymphocyte clones.

This phenomenon is well described in several autoimmune diseases and may contribute to persistent inflammation after the initiating trigger has resolved.

Polyclonal Lymphocyte Activation

Broad immune activation may transiently expand multiple B-cell and T-cell clones. In genetically predisposed individuals, rare autoreactive clones that escaped immune tolerance could theoretically proliferate alongside protective antiviral lymphocytes. Whether this mechanism is sufficient to initiate TM remains uncertain.

Innate Immunity
Pattern Recognition Receptors

The innate immune system detects pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs) through pattern recognition receptors, including:

  • Toll-like receptors (TLRs),
  • RIG-I-like receptors,
  • NOD-like receptors,
  • cGAS–STING pathway sensors.

Activation of these receptors induces type I interferons and inflammatory cytokines that bridge innate and adaptive immunity.

Type I Interferon Responses

Type I interferons (IFN-α and IFN-β) are central to antiviral defense. They:

  • enhance antigen presentation,
  • activate dendritic cells,
  • increase natural killer cell activity,
  • promote cytotoxic T-cell differentiation.

Interferon signaling is tightly regulated. Excessive or prolonged activation has been implicated in several autoimmune conditions. Whether dysregulated interferon responses contribute to rare post-vaccination inflammatory syndromes remains an active area of investigation.

Adaptive Immunity
CD4+ T Cells

Naïve CD4+ lymphocytes differentiate into several functional subsets:

Th1 Cells

Th1 cells produce:

  • interferon-γ,
  • IL-2,
  • TNF-α.

These cytokines activate macrophages and promote cellular immunity. Th1 predominance is commonly observed in inflammatory demyelinating disorders.

Th17 Cells

Th17 lymphocytes secrete:

  • IL-17A,
  • IL-17F,
  • IL-21,
  • IL-22.

IL-17 promotes:

  • endothelial activation,
  • neutrophil recruitment,
  • disruption of barrier integrity,
  • amplification of neuroinflammation.

Experimental autoimmune encephalomyelitis (EAE), an animal model of CNS autoimmunity, demonstrates a significant role for Th17 cells in inflammatory demyelination.

Regulatory T Cells

Tregs suppress excessive immune activation through:

  • IL-10,
  • TGF-β,
  • CTLA-4 signaling,
  • metabolic regulation.

Reduced Treg function has been associated with autoimmune diseases, though its specific role in vaccine-associated TM is not well defined.

CD8+ Cytotoxic T Cells

Activated CD8+ lymphocytes recognize antigen presented on MHC class I molecules and can induce apoptosis of target cells via:

  • perforin,
  • granzymes,
  • Fas–Fas ligand interactions.

In inflammatory myelopathies, CD8+ T cells may contribute to axonal injury and oligodendrocyte damage.

B Cells and Autoantibodies

B lymphocytes serve multiple functions:

  • antibody production,
  • antigen presentation,
  • cytokine secretion,
  • immune regulation.

Most reported cases of post-vaccination TM have not demonstrated disease-specific autoantibodies such as aquaporin-4 or MOG-IgG. Nevertheless, testing for these antibodies is clinically important because their presence suggests NMOSD or MOG antibody-associated disease rather than isolated TM.

Complement Activation

Complement activation contributes to tissue injury through:

  • opsonization,
  • chemotaxis,
  • membrane attack complex formation (C5b-9).

Complement fragments C3a and C5a recruit neutrophils and macrophages while amplifying inflammation. Deposition of complement proteins has been observed in several inflammatory demyelinating disorders, although evidence specific to vaccine-associated TM remains limited.

Blood–Spinal Cord Barrier Dysfunction

The blood–spinal cord barrier (BSCB) regulates immune cell trafficking into the spinal cord.

Inflammatory cytokines increase endothelial permeability by altering tight junction proteins such as:

  • claudins,
  • occludin,
  • zonula occludens-1.

Activated endothelial cells express adhesion molecules including:

  • ICAM-1,
  • VCAM-1,
  • E-selectin.

These changes facilitate leukocyte migration into spinal cord tissue.

Cellular Pathology
Astrocytes

Astrocytes maintain:

  • extracellular potassium balance,
  • glutamate homeostasis,
  • metabolic support,
  • blood–spinal cord barrier integrity.

During inflammation they become reactive, increasing expression of glial fibrillary acidic protein (GFAP). Reactive astrocytes release chemokines that recruit leukocytes but also produce neuroprotective molecules that aid tissue repair.

Microglia

Microglia are the resident macrophages of the CNS.

Following activation they:

  • present antigen,
  • release cytokines,
  • produce reactive oxygen species,
  • phagocytose myelin debris.

Microglial activation is an early feature of inflammatory CNS disorders and contributes both to injury and to subsequent repair.

Oligodendrocytes

Oligodendrocytes generate and maintain CNS myelin. Inflammatory injury may lead to:

  • demyelination,
  • impaired saltatory conduction,
  • axonal metabolic stress.

Surviving oligodendrocyte precursor cells can differentiate and remyelinate damaged axons, although remyelination is often incomplete.

Axonal Injury

Axonal degeneration is a major determinant of permanent disability.

Mechanisms include:

  • inflammatory cytokines,
  • mitochondrial dysfunction,
  • calcium overload,
  • oxidative stress,
  • excitotoxicity.

Biomarkers such as neurofilament light chain (NfL) correlate with axonal injury and are being investigated as prognostic indicators.

Genomic Susceptibility
Human Leukocyte Antigen (HLA)

HLA genes encode proteins responsible for antigen presentation to T cells.

Specific HLA alleles influence susceptibility to autoimmune diseases by determining which peptides are efficiently presented to the immune system. Associations have been described between particular HLA haplotypes and disorders such as multiple sclerosis, NMOSD, and MOG antibody-associated disease. Whether distinct HLA profiles predispose to vaccine-associated TM is not yet established because reported cases are few.

Cytokine Gene Variants

Polymorphisms affecting cytokines—including IL-6, IL-10, TNF-α, and interferon signaling pathways—have been associated with altered inflammatory responses in various autoimmune diseases. Their role in TM after vaccination remains speculative and requires larger genomic studies.

Transcriptomics

Bulk RNA sequencing and single-cell RNA sequencing (scRNA-seq) have transformed understanding of CNS inflammation by identifying cell-specific transcriptional programs.

Studies of inflammatory myelopathies have demonstrated:

  • activation of interferon-responsive genes,
  • increased chemokine expression,
  • microglial activation signatures,
  • expansion of inflammatory T-cell populations.

Application of these technologies to vaccine-associated TM is still limited but may clarify whether affected individuals share common immune pathways.

Epigenetics

Epigenetic regulation—including DNA methylation, histone modification, and non-coding RNAs—modulates immune cell differentiation without altering DNA sequence.

Environmental factors, infections, aging, and inflammatory stimuli can influence epigenetic states. Future studies may determine whether epigenetic predisposition contributes to rare autoimmune complications following vaccination or infection.

MRI, Cerebrospinal Fluid Analysis, and Biomarkers in Transverse Myelitis
Introduction

Magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) analysis, and emerging molecular biomarkers constitute the foundation of the modern diagnostic evaluation of transverse myelitis (TM). These complementary modalities assist clinicians in confirming spinal cord inflammation, excluding structural and infectious mimics, identifying underlying autoimmune disorders, estimating prognosis, and guiding treatment decisions. Although no single laboratory test is pathognomonic for TM, integration of neuroimaging, CSF findings, serologic testing, and clinical presentation substantially improves diagnostic accuracy.

In patients presenting with acute or subacute myelopathy, timely imaging and laboratory evaluation are essential because several disorders—including compressive myelopathy, spinal cord infarction, neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), infection, and neoplasm—require different therapeutic strategies.

Magnetic Resonance Imaging
Role of MRI

MRI is the imaging modality of choice for suspected TM because of its superior soft-tissue contrast and ability to visualize intramedullary inflammation. Imaging serves several purposes:

  • confirming spinal cord involvement,
  • determining lesion location and extent,
  • identifying active inflammation,
  • excluding compressive lesions,
  • detecting associated brain abnormalities,
  • monitoring disease evolution.

Current practice generally includes MRI of the entire spinal cord with and without gadolinium contrast. Brain MRI is recommended concurrently because cerebral lesions may suggest multiple sclerosis or other inflammatory disorders.

T2-Weighted Abnormalities

The most common MRI finding is a hyperintense intramedullary lesion on T2-weighted sequences reflecting edema, inflammation, and demyelination. Lesions vary in length from short-segment abnormalities to longitudinally extensive transverse myelitis (LETM), which extends across three or more contiguous vertebral segments.

Short-segment lesions are more frequently observed in multiple sclerosis, whereas LETM is classically associated with NMOSD but may also occur in MOGAD, systemic autoimmune diseases, infectious myelitis, and idiopathic TM.

Gadolinium Enhancement

Contrast enhancement indicates disruption of the blood–spinal cord barrier and active inflammation. Enhancement patterns are heterogeneous and may include:

  • diffuse enhancement,
  • patchy enhancement,
  • ring-like enhancement,
  • peripheral enhancement,
  • central cord enhancement.

The absence of enhancement does not exclude inflammatory myelitis, particularly in subacute or resolving lesions.

Diffusion-Weighted Imaging

Diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) mapping may help distinguish inflammatory lesions from spinal cord infarction. Restricted diffusion is more characteristic of acute ischemia, whereas inflammatory lesions often demonstrate more variable diffusion characteristics. Interpretation requires correlation with the clinical presentation and conventional MRI sequences.

Chronic MRI Findings

Follow-up imaging may demonstrate:

  • partial or complete resolution of signal abnormalities,
  • persistent T2 hyperintensity,
  • focal cord atrophy,
  • residual gliosis.

Spinal cord atrophy generally reflects irreversible tissue loss and is associated with poorer long-term neurological outcomes.

Cerebrospinal Fluid Analysis
Diagnostic Role

Lumbar puncture provides evidence of central nervous system inflammation and helps exclude infectious, neoplastic, and other inflammatory disorders. CSF evaluation is particularly useful when MRI findings are equivocal or when alternative diagnoses are under consideration.

Routine analysis typically includes:

  • cell count and differential,
  • protein concentration,
  • glucose concentration,
  • IgG index,
  • oligoclonal bands,
  • microbiologic studies when indicated.
Pleocytosis

Mild to moderate lymphocytic pleocytosis is frequently observed during the acute phase of inflammatory TM. Cell counts vary widely, and normal CSF does not exclude the diagnosis. Marked neutrophilic pleocytosis or very high leukocyte counts should prompt evaluation for bacterial infection or other alternative etiologies.

Protein Elevation

CSF protein is often modestly elevated, reflecting increased permeability of the blood–spinal cord barrier and inflammatory exudation. Markedly elevated protein concentrations may occur in severe inflammatory disease but are not specific for TM.

Oligoclonal Bands and IgG Index

Oligoclonal IgG bands and an elevated IgG index indicate intrathecal immunoglobulin synthesis. Their presence is common in multiple sclerosis but less frequent in isolated idiopathic TM. Detection of oligoclonal bands therefore raises consideration of an underlying demyelinating disorder and may influence long-term monitoring.

Infectious Studies

When clinically indicated, CSF testing should include evaluation for infectious pathogens that may produce acute myelitis, including herpesviruses, enteroviruses, human immunodeficiency virus, varicella-zoster virus, and other organisms based on epidemiologic risk factors. Appropriate microbiologic testing is guided by clinical presentation and exposure history.

Serologic Evaluation

Although not part of the CSF itself, serum testing complements CSF analysis and is essential for identifying specific autoimmune myelopathies.

Recommended studies may include:

  • aquaporin-4 IgG,
  • myelin oligodendrocyte glycoprotein (MOG) IgG,
  • antinuclear antibodies,
  • extractable nuclear antigen antibodies,
  • antiphospholipid antibodies,
  • vitamin B12 and copper levels,
  • inflammatory markers,
  • selected infectious serologies.

These investigations assist in distinguishing idiopathic TM from systemic autoimmune diseases, NMOSD, MOGAD, nutritional deficiencies, and infectious causes.

Emerging Biomarkers
Neurofilament Light Chain (NfL)

Neurofilament light chain is a structural protein released during axonal injury. Elevated concentrations in CSF and serum correlate with neuroaxonal damage in several inflammatory neurological disorders. While promising as a prognostic marker, its routine use in isolated TM awaits further validation.

Glial Fibrillary Acidic Protein (GFAP)

GFAP is an intermediate filament protein expressed by astrocytes. Increased GFAP concentrations may reflect astrocytic injury and have shown particular utility in disorders such as NMOSD. Their role in idiopathic TM and in rare TM cases occurring after vaccination remains under investigation.

Cytokine Profiles

Research studies have identified alterations in inflammatory mediators—including interleukin-6, interleukin-17, interferon-γ, and chemokines—in patients with inflammatory myelopathies. Although these findings provide insight into disease mechanisms, cytokine assays are not currently part of routine clinical practice because of variability among assays and limited disease specificity.

Advanced Molecular Profiling

High-throughput techniques such as proteomics, metabolomics, and single-cell transcriptomics are expanding understanding of spinal cord inflammation. These approaches may ultimately enable molecular classification of inflammatory myelopathies and facilitate personalized therapeutic strategies, but they remain largely investigational.

Diagnostic Integration

The diagnosis of TM relies on integrating clinical findings with imaging and laboratory evidence. MRI confirms intramedullary lesions and excludes compressive pathology, CSF supports an inflammatory process and helps exclude infection, while serologic testing identifies specific autoimmune syndromes. No single investigation is sufficient in isolation, underscoring the importance of a multidisciplinary diagnostic approach.

Clinical Presentation and Natural History of Transverse Myelitis
Introduction

Transverse myelitis (TM) represents a heterogeneous group of inflammatory spinal cord disorders characterized by neurological dysfunction attributable to immune-mediated injury within the spinal cord. The clinical phenotype depends on the anatomical level involved, the extent of inflammation, the degree of demyelination or axonal injury, and the underlying cause.

Although the term transverse historically implied involvement across the width of the spinal cord, modern imaging demonstrates that inflammatory lesions are often asymmetric and variable in distribution. Clinical manifestations arise from disruption of sensory pathways, corticospinal tracts, spinothalamic pathways, autonomic networks, and anterior horn structures.

The onset is typically acute or subacute, evolving over hours to several weeks. Rapid recognition is essential because early treatment may limit inflammatory injury and improve neurological recovery.

Clinical Definition and Diagnostic Criteria

The Transverse Myelitis Consortium Working Group established widely used diagnostic criteria requiring:

  1. Development of sensory, motor, or autonomic dysfunction attributable to spinal cord injury.
  2. Bilateral signs or symptoms, although not necessarily symmetric.
  3. Clearly defined sensory level.
  4. Exclusion of extra-axial compressive causes.
  5. Evidence of spinal cord inflammation demonstrated by MRI enhancement, CSF pleocytosis, elevated inflammatory markers, or other supportive findings.
  6. Progression to neurological nadir between 4 hours and 21 days.

These criteria distinguish TM from disorders such as spinal cord compression, vascular myelopathy, and peripheral neuropathies.

Initial Clinical Presentation
Motor Dysfunction

Weakness is among the most common presenting features of TM. It results from inflammatory injury to descending corticospinal pathways.

Motor manifestations may include:

  • lower extremity weakness,
  • upper extremity involvement in cervical lesions,
  • difficulty walking,
  • impaired balance,
  • spasticity,
  • hyperreflexia,
  • pathological reflexes.

During the earliest phase, patients may demonstrate spinal shock characterized by:

  • flaccid weakness,
  • reduced reflexes,
  • decreased muscle tone.

As spinal cord inflammation evolves, upper motor neuron signs frequently emerge:

  • increased tone,
  • spasticity,
  • brisk reflexes,
  • clonus,
  • Babinski responses.

Severity ranges from mild gait impairment to complete paralysis.

Sensory Dysfunction

Sensory abnormalities are highly characteristic of TM and may precede motor symptoms.

Common sensory complaints include:

  • numbness,
  • tingling,
  • burning pain,
  • electrical sensations,
  • altered temperature perception,
  • impaired vibration or proprioception.

A defining clinical feature is a sensory level, representing the approximate spinal segment below which sensation becomes abnormal.

Common patterns include:

  • thoracic sensory level → lower extremity symptoms,
  • cervical lesions → arm and leg involvement,
  • high cervical lesions → potential respiratory compromise.

Sensory symptoms may involve multiple modalities because inflammatory injury affects different ascending pathways.

Neuropathic Pain

Pain is frequent and may be severe. Mechanisms include:

  • inflammation of dorsal horn structures,
  • spinothalamic tract injury,
  • ectopic neuronal firing,
  • central sensitization.

Patients may describe:

  • burning pain,
  • stabbing sensations,
  • electric shock-like pain,
  • hypersensitivity to touch (allodynia).

Persistent neuropathic pain is one of the most disabling long-term complications.

Autonomic Dysfunction

The spinal cord contains critical autonomic pathways controlling bladder, bowel, sexual function, and cardiovascular regulation.

Bladder Dysfunction

Urinary symptoms are common and may include:

  • urinary retention,
  • urgency,
  • frequency,
  • incomplete emptying,
  • recurrent urinary tract infections.

Neurogenic bladder may result from impaired coordination between detrusor muscle contraction and sphincter relaxation.

Management often requires:

  • bladder scanning,
  • intermittent catheterization,
  • urodynamic evaluation,
  • anticholinergic therapy when appropriate.
Bowel Dysfunction

Patients may develop:

  • constipation,
  • fecal urgency,
  • impaired continence.

Loss of autonomic coordination can significantly affect quality of life.

Sexual Dysfunction

Spinal cord inflammation may impair:

  • erectile function,
  • genital sensation,
  • sexual response pathways.

These symptoms are frequently underreported but clinically important.

Fatigue and Systemic Symptoms

Although TM is primarily neurological, many patients experience:

  • profound fatigue,
  • sleep disturbance,
  • reduced endurance,
  • depression,
  • anxiety related to disability.

Fatigue may persist even after motor recovery and may reflect ongoing neurological dysfunction, altered autonomic regulation, inflammation, and psychological adaptation.

Temporal Evolution of Disease
Acute Phase

The acute phase typically progresses over hours to several days.

Early symptoms may include:

  • paresthesias,
  • sensory changes,
  • back or limb pain,
  • weakness.

Neurological deterioration may continue until inflammatory injury reaches its peak.

The nadir is generally reached within approximately 21 days, although severe cases may progress more rapidly.

Subacute Phase

Following initiation of therapy and resolution of acute inflammation, recovery begins.

Processes contributing to recovery include:

  • reduction of inflammatory infiltration,
  • restoration of conduction in partially demyelinated axons,
  • remyelination,
  • neural plasticity.

Recovery is variable and depends heavily on lesion severity and anatomical location.

Chronic Phase

Some patients experience incomplete recovery with persistent:

  • weakness,
  • sensory loss,
  • spasticity,
  • neuropathic pain,
  • bladder dysfunction,
  • fatigue.

Chronic disability generally reflects irreversible axonal injury rather than ongoing inflammation alone.

Clinical Patterns Based on Lesion Location
Cervical Myelitis

Cervical spinal cord involvement may produce:

  • arm and leg weakness,
  • sensory loss in all extremities,
  • hand dysfunction,
  • respiratory muscle impairment in severe cases.

High cervical lesions carry greater risk because of proximity to respiratory pathways.

Thoracic Myelitis

Thoracic involvement is common and may produce:

  • bilateral leg weakness,
  • trunk sensory level,
  • bowel and bladder dysfunction,
  • gait impairment.
Longitudinally Extensive Transverse Myelitis

LETM refers to lesions extending three or more vertebral segments.

It is strongly associated with:

  • aquaporin-4 antibody-positive NMOSD,
  • MOGAD,
  • systemic autoimmune disease,

but may also occur in idiopathic inflammatory TM.

LETM often causes more severe deficits and requires careful evaluation for underlying systemic or antibody-mediated disease.

Relationship to COVID-19 Vaccination

Cases of TM have been reported following COVID-19 vaccination. Reported clinical presentations generally resemble other inflammatory TM syndromes, including:

  • sensory disturbance,
  • lower extremity weakness,
  • autonomic dysfunction,
  • MRI-confirmed spinal cord lesions,
  • inflammatory CSF findings in some patients.

Available evidence does not demonstrate a unique clinical phenotype that reliably distinguishes temporally associated post-vaccination cases from other forms of TM. Most published reports consist of individual cases or small series, limiting conclusions regarding causation, severity, and prognosis.

Important considerations include:

  • TM occurs spontaneously,
  • infections can trigger TM,
  • SARS-CoV-2 infection itself has been associated with neurological inflammation,
  • background incidence must be considered when evaluating temporal associations.
Prognostic Factors

Several factors influence recovery.

Favorable Prognostic Indicators

Associated with better outcomes:

  • early treatment,
  • incomplete paralysis,
  • preserved sensation,
  • rapid clinical improvement,
  • limited MRI lesion burden,
  • absence of severe axonal injury.
Poor Prognostic Indicators

Associated with worse outcomes:

  • complete paralysis at onset,
  • severe sensory loss,
  • extensive spinal cord lesions,
  • sphincter dysfunction,
  • delayed treatment,
  • persistent MRI abnormalities,
  • significant axonal injury biomarkers.
Long-Term Functional Outcomes

Recovery trajectories vary substantially.

Some patients regain near-normal function, while others experience permanent disability.

Possible long-term outcomes include:

  • independent ambulation,
  • assisted walking,
  • wheelchair dependence,
  • chronic pain syndromes,
  • neurogenic bladder,
  • occupational limitations.

Functional recovery may continue for months or even years due to ongoing neuroplastic adaptation.

Rehabilitation Considerations

Recovery is not determined solely by immune suppression. Rehabilitation plays a central role.

Important components include:

  • physical therapy,
  • gait training,
  • strengthening,
  • balance therapy,
  • occupational therapy,
  • bladder management,
  • pain management,
  • psychological support.

Neurorehabilitation aims to maximize function despite residual neurological deficits.

Differential Diagnosis of Transverse Myelitis
Introduction

Transverse myelitis (TM) is a clinical syndrome rather than a single disease entity. The diagnosis requires evidence of spinal cord dysfunction and inflammation while excluding alternative causes of myelopathy. This distinction is critically important because treatment strategies, prognosis, and recurrence risk vary substantially among different disorders that can present with similar neurological findings.

The differential diagnosis of TM is broad and includes:

  • immune-mediated demyelinating disorders,
  • infectious myelitis,
  • vascular disorders,
  • compressive lesions,
  • metabolic and nutritional disorders,
  • toxic causes,
  • neoplastic infiltration,
  • granulomatous disease,
  • paraneoplastic syndromes,
  • degenerative spinal disease.

A structured diagnostic approach combining clinical history, neurological examination, MRI characteristics, cerebrospinal fluid (CSF) analysis, serologic testing, and systemic evaluation is required.

Multiple Sclerosis-Associated Myelitis
Overview

Multiple sclerosis (MS) is one of the most important inflammatory disorders to distinguish from isolated TM. MS is characterized by immune-mediated demyelination involving the central nervous system, typically affecting the brain, optic nerves, and spinal cord.

Spinal cord involvement occurs in approximately 20–30% of patients during the disease course, although microscopic lesions may be more frequent.

Clinical Features Suggestive of Multiple Sclerosis

Features favoring MS include:

  • younger age at onset,
  • episodic neurological symptoms,
  • optic neuritis,
  • sensory symptoms separated in time and space,
  • cognitive or visual pathway involvement,
  • family history of demyelinating disease.

MRI Characteristics

MS spinal cord lesions typically demonstrate:

  • short-segment involvement,
  • peripheral location within the cord,
  • asymmetric lesions,
  • involvement of the cervical spinal cord.

Brain MRI is particularly valuable. Findings supportive of MS include:

  • periventricular lesions,
  • juxtacortical lesions,
  • infratentorial lesions,
  • corpus callosum involvement.
CSF Findings

Common findings include:

  • oligoclonal IgG bands,
  • elevated IgG index,
  • evidence of intrathecal immune activation.

The presence of oligoclonal bands does not prove MS, but in the appropriate clinical context it substantially increases diagnostic probability.

Neuromyelitis Optica Spectrum Disorder (NMOSD)
Overview

NMOSD is an autoimmune inflammatory disorder primarily associated with antibodies directed against aquaporin-4 (AQP4), a water channel expressed on astrocytic end-feet surrounding blood vessels.

Unlike MS, NMOSD primarily targets astrocytes rather than oligodendrocytes.

Clinical Features

Typical manifestations include:

  • optic neuritis,
  • longitudinally extensive transverse myelitis,
  • area postrema syndrome (intractable nausea and vomiting),
  • brainstem syndromes,
  • diencephalic involvement.

Spinal attacks are frequently severe and may produce profound weakness and autonomic dysfunction.

MRI Features

Characteristic findings include:

  • lesions extending three or more vertebral segments,
  • central cord involvement,
  • swelling during acute attacks,
  • possible cavitation or atrophy after severe injury.
Laboratory Diagnosis

Serum testing for AQP4-IgG using cell-based assays is highly specific.

Identification of AQP4 antibodies changes:

  • prognosis,
  • recurrence risk,
  • long-term treatment strategy.

Patients with AQP4-positive NMOSD generally require chronic immunotherapy because untreated disease may produce cumulative disability.

Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD)
Overview

MOGAD is an inflammatory demyelinating disorder associated with antibodies targeting myelin oligodendrocyte glycoprotein.

It is increasingly recognized as a distinct disease rather than a variant of MS.

Clinical Manifestations

MOGAD may present with:

  • optic neuritis,
  • acute disseminated encephalomyelitis,
  • transverse myelitis,
  • brainstem inflammation.
Spinal Cord Features

MOG-associated myelitis may demonstrate:

  • longitudinally extensive lesions,
  • involvement of the conus medullaris,
  • central cord abnormalities.
Prognosis

Compared with AQP4-positive NMOSD, MOGAD may have a higher likelihood of substantial recovery, although relapses can occur.

Acute Disseminated Encephalomyelitis (ADEM)
Overview

ADEM is an inflammatory demyelinating disorder characterized by widespread CNS inflammation, typically following infection or immune stimulation.

It occurs more commonly in children but can occur in adults.

Clinical Features

ADEM differs from isolated TM because it usually includes:

  • encephalopathy,
  • altered mental status,
  • diffuse neurological symptoms.
MRI Findings

Brain MRI typically shows:

  • large bilateral lesions,
  • poorly marginated abnormalities,
  • deep gray matter involvement.
Spinal Cord Infarction
Overview

Spinal cord ischemia can closely mimic TM but requires entirely different management.

Causes include:

  • aortic disease,
  • vascular surgery complications,
  • hypotension,
  • embolic disease,
  • vascular malformations.
Clinical Clues

Features suggesting infarction include:

  • sudden onset within minutes to hours,
  • severe back pain,
  • rapid maximal deficit,
  • vascular risk factors.
MRI Findings

Typical findings include:

  • anterior spinal artery territory involvement,
  • diffusion restriction,
  • “owl-eye” appearance on axial imaging.
Compressive Myelopathy
Overview

Compression must always be excluded before diagnosing inflammatory TM.

Causes include:

  • herniated discs,
  • spinal stenosis,
  • tumors,
  • epidural abscess,
  • hematoma.
Clinical Features

Compression may produce:

  • progressive weakness,
  • radicular pain,
  • asymmetric symptoms,
  • mechanical back pain.
MRI Findings

MRI demonstrates:

  • extradural mass effect,
  • spinal canal narrowing,
  • cord compression,
  • possible edema.

Unlike inflammatory TM, treatment may require urgent surgical intervention.

Infectious Myelitis
Viral Causes

Viruses associated with myelitis include:

  • herpes simplex virus,
  • varicella-zoster virus,
  • cytomegalovirus,
  • Epstein–Barr virus,
  • enteroviruses,
  • HIV.
Clinical Features

Clues include:

  • fever,
  • systemic illness,
  • immunosuppression,
  • meningitis symptoms.
Diagnostic Testing

Evaluation may include:

  • CSF PCR,
  • serologic testing,
  • microbial cultures when appropriate.

Early recognition is essential because antiviral or antimicrobial therapy may be lifesaving.

Neurosarcoidosis
Overview

Sarcoidosis can involve the spinal cord through granulomatous inflammation.

Features Suggestive of Neurosarcoidosis

Associated findings may include:

  • pulmonary sarcoidosis,
  • cranial neuropathies,
  • systemic inflammatory disease.

MRI may demonstrate:

  • longitudinal enhancement,
  • leptomeningeal involvement,
  • cord swelling.

Diagnosis may require systemic imaging or tissue biopsy.

Systemic Autoimmune Diseases
Systemic Lupus Erythematosus (SLE)

SLE-associated myelitis may occur through:

  • immune complex deposition,
  • vasculitis,
  • antibody-mediated injury.

Associated findings may include:

  • ANA positivity,
  • anti-double-stranded DNA antibodies,
  • complement abnormalities.
Sjögren Syndrome

Sjögren-related myelitis may mimic NMOSD and may require evaluation for:

  • anti-Ro/SSA antibodies,
  • systemic symptoms,
  • salivary gland involvement.
Paraneoplastic Myelopathy
Overview

Paraneoplastic neurological syndromes result from immune responses directed against tumor-associated antigens that cross-react with nervous system proteins.

Associated Antibodies

Examples include:

  • anti-Hu,
  • CRMP5,
  • amphiphysin antibodies.
Clinical Features

Often characterized by:

  • progressive course,
  • poor response to immunotherapy,
  • associated malignancy.

Evaluation may include:

  • CT imaging,
  • PET scanning,
  • age-appropriate cancer screening.
Metabolic and Nutritional Myelopathies
Vitamin B12 Deficiency

Subacute combined degeneration caused by vitamin B12 deficiency produces:

  • posterior column dysfunction,
  • impaired vibration sense,
  • gait instability.

MRI may show dorsal column abnormalities.

Copper Deficiency

Copper deficiency can resemble B12 deficiency and may occur after:

  • bariatric surgery,
  • excessive zinc exposure,
  • malabsorption disorders.
Toxic Myelopathies

Potential toxic causes include:

  • nitrous oxide exposure,
  • certain chemotherapeutic agents,
  • radiation injury.

Recognition depends heavily on exposure history.

Degenerative Cervical and Lumbar Disease

Spinal degenerative disease may produce:

  • gait impairment,
  • weakness,
  • sensory symptoms.

However, degenerative disease usually produces chronic mechanical compression rather than acute inflammatory lesions.

Diagnostic Approach

A practical diagnostic algorithm includes:

Step 1: Confirm Myelopathy

Identify:

  • upper motor neuron signs,
  • sensory level,
  • bowel/bladder involvement.
Step 2: MRI Entire Spinal Cord

Evaluate for:

  • inflammation,
  • compression,
  • vascular patterns,
  • tumor.
Step 3: CSF Analysis

Assess:

  • inflammation,
  • infection,
  • intrathecal immune activity.
Step 4: Autoimmune Testing

Include:

  • AQP4-IgG,
  • MOG-IgG,
  • systemic autoimmune markers.
Step 5: Search for Secondary Causes

Consider:

  • infection,
  • malignancy,
  • nutritional deficiency,
  • vascular disease.
Importance in Post-COVID Vaccine Reports

When TM occurs after COVID-19 vaccination, the same rigorous differential diagnosis applies. A temporal relationship alone does not distinguish vaccine-associated inflammatory TM from:

  • first presentation of MS,
  • NMOSD,
  • MOGAD,
  • spinal infarction,
  • infection,
  • malignancy.

Comprehensive evaluation is therefore essential both for patient care and for accurate assessment of possible vaccine-related associations.

Treatment and Rehabilitation of Transverse Myelitis
Introduction

Management of transverse myelitis (TM) requires a multidisciplinary approach integrating rapid suppression of inflammation, prevention of secondary neurological injury, rehabilitation of functional deficits, and long-term monitoring for underlying immune-mediated disease.

Because TM represents a syndrome caused by multiple possible mechanisms—including idiopathic inflammation, antibody-mediated disease, infection, malignancy, vascular injury, and systemic autoimmune disorders—treatment must be individualized. Early recognition and initiation of appropriate therapy are associated with improved neurological outcomes, although recovery remains highly variable.

The therapeutic strategy generally consists of:

  1. Emergency evaluation and stabilization
  2. Identification and treatment of the underlying cause
  3. Acute immunotherapy when inflammatory TM is suspected
  4. Management of complications
  5. Comprehensive neurorehabilitation
  6. Long-term disease surveillance and prevention of relapse
Acute Management Principles
Exclusion of Compressive and Infectious Causes

Before initiating immunosuppression, clinicians must exclude conditions requiring alternative treatment.

Important exclusions include:

  • spinal cord compression,
  • epidural abscess,
  • spinal hematoma,
  • malignancy,
  • untreated infection.

High-dose corticosteroids can worsen certain infections; therefore, clinical judgment and appropriate testing are essential.

High-Dose Corticosteroid Therapy
Intravenous Methylprednisolone

High-dose intravenous methylprednisolone (IVMP) is considered first-line therapy for most suspected acute inflammatory TM.

A commonly used regimen is:

  • methylprednisolone 1 g intravenously daily for 3–5 days,

followed in many cases by:

  • an oral corticosteroid taper.
Mechanisms of Action

Corticosteroids suppress inflammation through multiple pathways:

  • inhibition of pro-inflammatory cytokine transcription,
  • reduction of lymphocyte activation,
  • decreased leukocyte migration,
  • stabilization of endothelial barriers,
  • suppression of macrophage activation.

They reduce inflammatory edema and may limit secondary axonal injury.

Clinical Response

Improvement may occur within days to weeks, but absence of early improvement does not necessarily indicate treatment failure. Some patients recover gradually over months as inflammation resolves and remyelination occurs.

Plasma Exchange (PLEX)
Indications

Plasma exchange is generally considered when:

  • severe neurological deficits are present,
  • corticosteroids produce inadequate improvement,
  • antibody-mediated disease is suspected.

It is particularly important in:

  • NMOSD,
  • severe inflammatory TM,
  • fulminant demyelinating disease.
Mechanism

PLEX removes circulating pathogenic factors, including:

  • autoantibodies,
  • immune complexes,
  • inflammatory cytokines,
  • complement components.

By rapidly reducing circulating immune mediators, plasma exchange may interrupt ongoing tissue injury.

Treatment Protocols

Common protocols involve:

  • 5–7 exchanges,
  • performed over approximately 1–2 weeks.

Response is variable, but early initiation is associated with improved outcomes in severe inflammatory demyelinating disorders.

Intravenous Immunoglobulin (IVIG)
Mechanisms

IVIG contains pooled immunoglobulin from thousands of donors and has immunomodulatory effects including:

  • Fc receptor blockade,
  • suppression of pathogenic antibodies,
  • modulation of complement activation,
  • enhancement of regulatory immune pathways.
Role in TM

Evidence supporting IVIG specifically for idiopathic TM is less robust than for plasma exchange, but it may be considered in:

  • steroid-refractory cases,
  • patients unable to undergo plasma exchange,
  • selected immune-mediated disorders.
Escalation Immunotherapy

When TM reflects a chronic autoimmune disorder rather than a single monophasic inflammatory event, long-term immune therapy may be required.

Rituximab
Mechanism

Rituximab is a monoclonal antibody targeting CD20-positive B lymphocytes.

B-cell depletion reduces:

  • antibody production,
  • antigen presentation,
  • inflammatory cytokine release.
Clinical Applications

Rituximab is widely used in:

  • NMOSD,
  • refractory autoimmune myelitis,
  • some MOGAD cases.

Its role in isolated monophasic TM remains less defined.

Other Immunosuppressive Therapies

Depending on the underlying diagnosis, additional therapies may include:

  • mycophenolate mofetil,
  • azathioprine,
  • cyclophosphamide,
  • tocilizumab,
  • other targeted biologic agents.

Treatment selection depends on:

  • antibody status,
  • relapse risk,
  • systemic autoimmune features,
  • prior treatment response.
Management of Specific Disorders
Aquaporin-4 Positive NMOSD

NMOSD has a high relapse risk and typically requires long-term immunotherapy.

Approved or emerging therapies include:

  • complement inhibition,
  • B-cell depletion,
  • IL-6 receptor blockade,
  • other immune-targeted approaches.

Preventing future attacks is critical because cumulative spinal cord injury often produces permanent disability.

MOG Antibody Disease

MOGAD management depends on:

  • severity,
  • relapse history,
  • antibody persistence,
  • clinical phenotype.

Some patients experience a single attack, whereas others require long-term immunotherapy.

Rehabilitation Medicine
Importance of Early Rehabilitation

Recovery from TM depends not only on immune suppression but also on restoration of function through neurorehabilitation.

Goals include:

  • maximizing independence,
  • preventing complications,
  • improving mobility,
  • reducing pain,
  • enhancing quality of life.
Physical Therapy

Physical therapy focuses on:

Strength Training

Targets:

  • residual muscle weakness,
  • endurance limitations,
  • deconditioning.
Gait Rehabilitation

May include:

  • balance exercises,
  • assistive devices,
  • treadmill training,
  • robotic-assisted therapy in selected settings.
Spasticity Management

Spasticity may be treated with:

  • stretching programs,
  • physical therapy,
  • oral medications such as baclofen or tizanidine,
  • botulinum toxin injections when appropriate.
Occupational Therapy

Occupational therapy addresses:

  • upper extremity function,
  • activities of daily living,
  • adaptive equipment,
  • workplace modifications.

Patients with hand dysfunction or sensory loss may benefit substantially from targeted interventions.

Bladder and Bowel Management
Neurogenic Bladder

Management may include:

  • intermittent catheterization,
  • bladder training,
  • anticholinergic medications,
  • beta-3 adrenergic agonists,
  • urodynamic assessment.

Prevention of recurrent urinary tract infections is an important goal.

Neurogenic Bowel

Approaches include:

  • dietary modification,
  • scheduled bowel programs,
  • fiber optimization,
  • stool softeners,
  • pharmacologic therapies when needed.
Neuropathic Pain Management

Persistent pain is among the most disabling consequences of TM.

Treatment options include:

Anticonvulsant Medications

Examples:

  • gabapentin,
  • pregabalin.
Antidepressant-Based Neuropathic Agents

Examples:

  • duloxetine,
  • venlafaxine,
  • tricyclic antidepressants.
Nonpharmacological Approaches

Include:

  • cognitive behavioral therapy,
  • desensitization techniques,
  • physical therapy,
  • mindfulness-based approaches.
Fatigue Management

Fatigue may persist despite neurological improvement.

Strategies include:

  • sleep optimization,
  • graded activity programs,
  • treatment of depression,
  • energy conservation techniques.

In selected patients, medications may be considered, although evidence is limited.

Psychological and Social Support

TM can produce profound life changes due to:

  • loss of mobility,
  • altered independence,
  • chronic pain,
  • occupational disruption.

Psychological support should address:

  • depression,
  • anxiety,
  • adjustment,
  • caregiver burden.
Rehabilitation After Vaccine-Associated TM

Published cases of TM occurring after COVID-19 vaccination have generally been managed according to established TM treatment principles rather than with vaccine-specific therapies.

Reported approaches have included:

  • corticosteroids,
  • plasma exchange,
  • IVIG,
  • rehabilitation.

There is currently no evidence that post-vaccination TM requires a fundamentally different therapeutic approach from other inflammatory TM syndromes.

Emerging Therapeutic Strategies
Targeted Cytokine Modulation

Research is exploring therapies targeting inflammatory pathways including:

  • IL-6,
  • IL-17,
  • complement activation,
  • B-cell signaling.
Remyelination Therapies

Potential future approaches include:

  • oligodendrocyte precursor cell stimulation,
  • neuroprotective agents,
  • regenerative medicine strategies.
Biomarker-Guided Treatment

Future precision medicine approaches may use:

  • immune-cell profiling,
  • genomic signatures,
  • cytokine patterns,
  • neurofilament measurements,

to identify which patients require aggressive therapy.

Summary

Treatment of transverse myelitis requires rapid recognition, exclusion of mimicking disorders, and prompt suppression of immune-mediated injury when inflammation is suspected. Corticosteroids remain the cornerstone of acute therapy, with plasma exchange reserved for severe or steroid-resistant cases. Long-term management depends on identifying underlying disorders such as NMOSD, MOGAD, or systemic autoimmune disease.

Rehabilitation is essential because recovery depends not only on eliminating inflammation but also on restoring neurological function through adaptation, strengthening, and neuroplasticity.

Long-Term Prognosis and Outcomes of Transverse Myelitis
Introduction

The long-term prognosis of transverse myelitis (TM) is highly variable and depends on multiple interacting factors, including the severity of the initial inflammatory injury, anatomical location of the lesion, degree of axonal damage, underlying etiology, speed of treatment initiation, and access to comprehensive rehabilitation.

Although some individuals experience substantial or near-complete recovery, others develop persistent neurological disability affecting mobility, sensation, bladder and bowel function, pain control, employment, and quality of life.

The concept of TM as a uniformly monophasic and self-limited disorder has evolved. Modern classification recognizes TM as a clinical syndrome arising from diverse mechanisms, including idiopathic inflammation, antibody-mediated disease, systemic autoimmune disorders, infection-associated inflammation, and other immune-mediated conditions. Long-term outcomes therefore depend heavily on establishing the correct diagnosis.

Patterns of Recovery
General Recovery Timeline

Neurological recovery typically follows a prolonged trajectory.

The major phases include:

Acute Phase

First days to several weeks

Dominated by:

  • inflammatory injury,
  • edema,
  • conduction block,
  • immune-mediated tissue damage.

The primary goal during this phase is rapid suppression of inflammation.

Early Recovery Phase

Weeks to months

Recovery occurs through:

  • resolution of inflammation,
  • restoration of conduction in partially damaged axons,
  • remyelination,
  • reduction of spinal cord edema.

Many patients demonstrate their greatest improvement during the first six months.

Late Recovery Phase

Six months to two years or longer

Continued improvement may occur through:

  • neural plasticity,
  • strengthening of preserved pathways,
  • rehabilitation-driven adaptation,
  • compensatory strategies.

Recovery after two years is less common but remains possible.

Functional Outcomes
Ambulation

Walking ability is one of the most important measures of functional recovery.

Outcomes range from:

  • complete return to independent walking,
  • walking with assistive devices,
  • limited household ambulation,
  • permanent wheelchair dependence.

Factors associated with improved walking outcomes include:

  • incomplete weakness at onset,
  • preserved sensation,
  • early neurological improvement,
  • limited spinal cord destruction.
Motor Recovery

Motor improvement depends on preservation of corticospinal tract integrity.

Patients may experience:

  • complete strength recovery,
  • residual weakness,
  • spasticity,
  • impaired coordination,
  • fatigue-related motor decline.

Persistent weakness often reflects irreversible axonal injury rather than ongoing inflammation.

Sensory Outcomes

Sensory recovery is often slower and less predictable than motor recovery.

Persistent sensory abnormalities may include:

  • numbness,
  • tingling,
  • impaired temperature sensation,
  • reduced vibration perception,
  • altered proprioception.

Some patients develop chronic dysesthesia, including:

  • burning sensations,
  • electric shock-like pain,
  • hypersensitivity to touch.

These symptoms may persist despite otherwise favorable motor recovery.

Chronic Neuropathic Pain
Mechanisms

Chronic pain after TM results from injury to:

  • spinothalamic pathways,
  • dorsal horn neurons,
  • ascending sensory tracts.

Inflammatory injury can induce:

  • central sensitization,
  • abnormal neuronal firing,
  • maladaptive neuroplastic changes.
Clinical Impact

Persistent pain can affect:

  • sleep,
  • mood,
  • mobility,
  • employment,
  • social functioning.

Pain management often requires a multimodal approach combining:

  • medications,
  • rehabilitation,
  • behavioral interventions,
  • physical therapies.
Autonomic Outcomes
Bladder Dysfunction

Neurogenic bladder is among the most important long-term complications.

Persistent problems may include:

  • urinary retention,
  • urgency,
  • incomplete emptying,
  • recurrent infections.

Long-term management may require:

  • urological follow-up,
  • urodynamic testing,
  • catheterization strategies,
  • medication.
Bowel Dysfunction

Chronic bowel dysfunction may involve:

  • constipation,
  • impaired continence,
  • difficulty coordinating bowel movements.

Structured bowel programs can significantly improve quality of life.

Sexual Dysfunction

Spinal cord inflammation can disrupt sexual function through:

  • impaired sensory pathways,
  • autonomic dysfunction,
  • psychological effects.

This complication is often underrecognized and undertreated.

Fatigue and Reduced Exercise Capacity

Fatigue is one of the most frequently reported chronic symptoms following inflammatory neurological disease.

Possible contributors include:

  • residual spinal cord dysfunction,
  • inefficient neural transmission,
  • autonomic dysregulation,
  • chronic pain,
  • sleep disruption,
  • psychological stress.

Unlike ordinary tiredness, neurological fatigue may occur after minimal exertion and may significantly restrict daily activities.

Cognitive and Emotional Consequences

Although TM primarily affects the spinal cord, patients frequently experience psychological consequences.

Common issues include:

  • depression,
  • anxiety,
  • adjustment difficulties,
  • reduced confidence,
  • fear of recurrence.

These effects often reflect the profound life changes caused by sudden neurological disability.

Comprehensive care should therefore include psychological and social support.

Relapse Risk
Idiopathic TM

Many cases of idiopathic TM are monophasic, meaning they occur once without recurrence.

However, recurrence risk increases when:

  • autoimmune markers are present,
  • MRI abnormalities suggest another demyelinating disorder,
  • specific antibodies are detected.
NMOSD

AQP4-positive NMOSD carries a high relapse risk.

Repeated attacks can produce:

  • cumulative spinal cord injury,
  • increasing disability,
  • permanent loss of function.

Long-term preventive therapy is usually required.

MOGAD

MOGAD has a variable course.

Some patients experience:

  • a single attack,
  • recurrent inflammatory episodes,
  • chronic relapsing disease.

Risk assessment depends on:

  • antibody persistence,
  • clinical phenotype,
  • relapse history.
Prognostic Biomarkers
MRI-Based Prognostic Factors

MRI features associated with more severe outcomes include:

  • extensive lesions,
  • marked spinal cord swelling,
  • persistent abnormalities,
  • cord atrophy.

However, MRI findings must be interpreted in the context of clinical examination because imaging severity does not always perfectly predict disability.

Neurofilament Light Chain

Elevated neurofilament light chain (NfL) reflects axonal injury.

Potential uses include:

  • estimating injury severity,
  • monitoring treatment response,
  • predicting recovery.

More research is needed before routine clinical implementation.

Immune Biomarkers

Potential future prognostic markers include:

  • cytokine signatures,
  • immune-cell profiles,
  • autoantibody patterns,
  • genetic susceptibility markers.

These may eventually allow personalized prediction of recovery and relapse risk.

Prognosis in COVID-19 Vaccine-Temporally Associated TM
Current Evidence

Published reports of TM following COVID-19 vaccination are primarily composed of:

  • individual case reports,
  • small case series,
  • pharmacovigilance signals.

Most reported patients have received standard TM therapies, including:

  • corticosteroids,
  • plasma exchange,
  • intravenous immunoglobulin,
  • rehabilitation.

The clinical outcomes reported are heterogeneous, ranging from substantial recovery to persistent disability.

Limitations of Current Knowledge

Several factors limit conclusions regarding long-term prognosis specifically after vaccination:

  1. Small number of confirmed cases.
  2. Lack of standardized follow-up.
  3. Variable diagnostic criteria.
  4. Differences in treatment timing.
  5. Difficulty separating vaccine-associated cases from background TM incidence.

At present, there is insufficient evidence to conclude that vaccine-associated TM has a distinct prognosis compared with other inflammatory TM syndromes.

Quality of Life Outcomes

Disability from TM extends beyond neurological impairment.

Important domains include:

  • independence,
  • employment,
  • mobility,
  • relationships,
  • emotional health,
  • social participation.

Patient-reported outcomes are increasingly recognized as essential measures of treatment success.

Importance of Long-Term Follow-Up

Patients diagnosed with TM require ongoing monitoring because:

  • autoimmune disorders may declare themselves later,
  • relapses may occur,
  • rehabilitation needs evolve,
  • complications such as bladder dysfunction may persist.

Follow-up commonly includes:

  • neurological examination,
  • MRI when clinically indicated,
  • antibody monitoring in selected cases,
  • rehabilitation reassessment.
Future Directions in Prognostication

Future research priorities include:

Artificial Intelligence and Imaging Analysis

Machine-learning approaches may identify MRI patterns predictive of:

  • recovery,
  • relapse,
  • treatment response.
Precision Immunology

Advanced immune profiling may allow classification of patients according to:

  • dominant inflammatory pathway,
  • autoimmune mechanism,
  • optimal therapy.
Regenerative Approaches

Emerging strategies aim to promote:

  • remyelination,
  • axonal repair,
  • neuroprotection.

Potential approaches include:

  • oligodendrocyte precursor stimulation,
  • neurotrophic therapies,
  • cellular therapies.
Summary

Long-term outcomes after transverse myelitis are highly variable. Early recognition, appropriate immunotherapy, accurate identification of underlying disease mechanisms, and intensive rehabilitation strongly influence recovery. While some patients regain substantial neurological function, others experience chronic disability involving mobility, pain, autonomic dysfunction, and fatigue.

For TM occurring after COVID-19 vaccination, available evidence suggests that reported cases generally resemble other inflammatory TM syndromes, but the rarity of the condition limits definitive conclusions regarding prognosis. Continued surveillance and prospective longitudinal studies are required.

Future Therapeutics and Research Priorities in Transverse Myelitis
Introduction

Despite substantial advances in the diagnosis and treatment of inflammatory myelopathies, transverse myelitis (TM) remains a disorder with significant unmet medical needs. Current therapies primarily target immune suppression after neurological injury has already begun. While corticosteroids, plasma exchange, and immunomodulatory therapies can reduce inflammation, they do not directly restore lost axons, replace damaged myelin, or reverse established spinal cord injury.

Future progress will depend on a transition from broad immunosuppression toward precision neuroimmunology, integrating genomics, molecular biomarkers, advanced imaging, cellular biology, and regenerative medicine.

Research priorities include:

  • improved prediction of disease mechanisms,
  • earlier diagnosis,
  • individualized immunotherapy,
  • prevention of irreversible neurological injury,
  • enhancement of remyelination,
  • promotion of axonal regeneration.
Limitations of Current Therapeutic Approaches
Nonspecific Immunosuppression

The current cornerstone of TM treatment is suppression of inflammation. However, therapies such as corticosteroids and plasma exchange have limitations:

  • they do not identify the specific immune pathway involved,
  • they may suppress protective immunity,
  • they may produce significant adverse effects,
  • they do not directly repair damaged neural tissue.

Inflammation is biologically complex, and immune cells may simultaneously contribute to injury and repair. Broad suppression may therefore eliminate beneficial immune functions along with harmful responses.

Treatment Timing

A major challenge is the delay between disease onset and therapy initiation.

By the time many patients receive treatment:

  • inflammatory infiltration may already be extensive,
  • oligodendrocytes may be injured,
  • axonal degeneration may have begun.

Earlier recognition through improved biomarkers could allow intervention before irreversible damage occurs.

Precision Immunology
Immune Phenotyping

Future approaches may classify TM according to dominant immune mechanisms rather than clinical appearance alone.

Potential immune profiles include:

  • T-cell predominant inflammation,
  • antibody-mediated disease,
  • complement-driven injury,
  • macrophage-dominant inflammation,
  • interferon-driven immune activation.

Technologies enabling this approach include:

  • single-cell RNA sequencing,
  • mass cytometry,
  • immune repertoire sequencing,
  • proteomics.
Personalized Immunotherapy

Rather than treating all patients with the same immunosuppressive strategy, future therapy may be guided by:

  • antibody status,
  • cytokine signatures,
  • genetic susceptibility,
  • immune-cell composition.

For example:

  • AQP4-positive NMOSD may benefit from complement or B-cell targeted therapy.
  • MOG antibody disease may require different strategies.
  • T-cell mediated inflammatory disorders may require alternative approaches.
Biomarker Development
Diagnostic Biomarkers

Current diagnosis depends heavily on:

  • clinical examination,
  • MRI,
  • CSF analysis.

Future biomarkers may permit earlier and more precise diagnosis.

Potential candidates include:

  • serum neurofilament light chain,
  • glial fibrillary acidic protein,
  • cytokine profiles,
  • autoantibody panels,
  • extracellular vesicle markers.
Prognostic Biomarkers

Predicting recovery remains difficult.

Future prognostic tools may integrate:

  • MRI lesion characteristics,
  • quantitative spinal cord imaging,
  • serum biomarkers,
  • genomic data,
  • clinical severity scores.

Such models could identify patients who require aggressive early therapy.

Genomics and Epigenomics
Genetic Susceptibility

Autoimmune neurological diseases often reflect interactions between:

  • genetic predisposition,
  • environmental exposures,
  • immune activation.

Future studies may investigate:

  • HLA associations,
  • interferon pathway variants,
  • immune checkpoint genes,
  • cytokine-related polymorphisms.

Large international cohorts will be necessary because TM is rare.

Epigenetic Regulation

Epigenetic mechanisms regulate immune-cell behavior through:

  • DNA methylation,
  • histone modification,
  • microRNA regulation.

Environmental triggers, infections, aging, and immune stimulation can alter these pathways.

Future research may determine whether epigenetic signatures identify individuals predisposed to inflammatory neurological complications.

Advanced Imaging Technologies
Quantitative MRI

Conventional MRI identifies lesions but provides limited information about tissue integrity.

Advanced techniques include:

Diffusion Tensor Imaging (DTI)

Measures:

  • axonal organization,
  • white matter integrity.
Magnetization Transfer Imaging

Provides information regarding:

  • myelin content,
  • demyelination severity.
MR Spectroscopy

Evaluates:

  • neuronal metabolites,
  • inflammation,
  • tissue injury.
Artificial Intelligence in Imaging

Machine learning may improve:

  • lesion detection,
  • outcome prediction,
  • differentiation between TM and mimicking disorders.

AI-assisted imaging could eventually provide individualized estimates of:

  • recovery probability,
  • relapse risk,
  • treatment response.
Neuroprotection

Current therapies primarily suppress inflammation. Future treatments may also protect vulnerable neural structures.

Potential targets include:

Mitochondrial Protection

Inflammatory injury increases:

  • oxidative stress,
  • mitochondrial dysfunction,
  • energy failure.

Agents targeting mitochondrial pathways may reduce secondary axonal degeneration.

Glutamate Regulation

Inflammation can cause excitotoxic injury through excessive glutamate signaling.

Neuroprotective strategies may include modulation of:

  • NMDA receptors,
  • calcium channels,
  • excitotoxic pathways.
Oxidative Stress Reduction

Potential approaches include:

  • antioxidant therapies,
  • enhancement of endogenous protective pathways.
Remyelination Strategies
Oligodendrocyte Precursor Cells

The adult spinal cord contains precursor cells capable of generating new oligodendrocytes.

Therapeutic goals include:

  • stimulating precursor activation,
  • enhancing migration,
  • improving maturation,
  • increasing myelin repair.
Pharmacologic Remyelination

Research is investigating compounds that influence:

  • differentiation pathways,
  • growth factors,
  • signaling molecules.

The goal is to restore conduction in damaged but surviving axons.

Cellular and Regenerative Medicine
Stem Cell Approaches

Experimental strategies include:

  • neural stem cells,
  • mesenchymal stromal cells,
  • oligodendrocyte precursor cell transplantation.

Potential benefits include:

  • immunomodulation,
  • trophic support,
  • remyelination.

However, significant challenges remain:

  • safety,
  • immune rejection,
  • appropriate cell targeting,
  • long-term integration.
Digital Medicine and Remote Monitoring

Emerging technologies may improve long-term care.

Potential tools include:

  • wearable mobility sensors,
  • smartphone-based neurological assessments,
  • home monitoring of gait,
  • digital fatigue tracking.

These approaches may detect subtle changes before clinical deterioration becomes apparent.

Research Priorities for COVID-19 Vaccine-Temporally Associated TM
Establishing Causality

Future studies require:

  • large population-based cohorts,
  • standardized case definitions,
  • active surveillance systems,
  • comparison with background incidence.

Important questions include:

  • Does vaccination increase risk above baseline?
  • Are specific vaccine platforms associated with different risks?
  • Are particular genetic or immune profiles associated with susceptibility?
Mechanistic Studies

Future investigations should examine:

  • immune-cell phenotypes,
  • autoantibody development,
  • molecular mimicry hypotheses,
  • interferon responses,
  • complement activation,
  • genomic susceptibility.

The goal is not merely to identify associations but to determine whether specific biological pathways are reproducibly involved.

International Registries

Because TM is rare, progress requires collaboration through:

  • multinational registries,
  • standardized clinical datasets,
  • longitudinal follow-up.

Essential data elements should include:

  • vaccine exposure,
  • prior infection history,
  • immune status,
  • MRI findings,
  • CSF results,
  • antibody testing,
  • treatments,
  • outcomes.
Clinical Trial Priorities

Future trials should evaluate:

Earlier Intervention

Studies should determine whether treatment within hours or days improves outcomes compared with delayed therapy.

Combination Therapy

Potential approaches include:

  • corticosteroids plus plasma exchange,
  • targeted biologics plus standard therapy,
  • neuroprotective agents plus immune modulation.
Biomarker-Guided Trials

Instead of treating all TM patients identically, trials may enroll patients based on:

  • immune signatures,
  • antibody profiles,
  • molecular classification.
Ethical and Public Health Considerations

Rare neurological events following vaccination require careful balance between:

  • recognizing legitimate adverse events,
  • maintaining scientific rigor,
  • avoiding unsupported causal conclusions,
  • preserving public confidence in evidence-based medicine.

Pharmacovigilance systems must continue monitoring rare events while incorporating appropriate epidemiologic methods.

Final Conclusions

Transverse myelitis represents a complex intersection of neuroimmunology, genetics, inflammation, and tissue repair. Although current therapies can reduce immune-mediated injury, many patients continue to experience long-term neurological consequences because existing treatments do not fully address axonal loss and failed regeneration.

The future of TM care will likely involve:

  • molecular classification of disease,
  • precision immunotherapy,
  • predictive biomarkers,
  • advanced imaging,
  • neuroprotective therapies,
  • regenerative approaches.

Regarding TM occurring after COVID-19 vaccination, available evidence supports continued surveillance and mechanistic investigation. The rarity of reported cases, biological complexity, and background occurrence of TM require careful interpretation. Future research should focus on identifying reproducible biological signatures and improving outcomes for all patients with inflammatory myelopathies.

References
  1. Frohman EM, Wingerchuk DM. Transverse myelitis. N Engl J Med. 2010.
  2. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002.
  3. Lassmann H. Pathology of inflammatory diseases of the central nervous system. Cold Spring Harb Perspect Med. 2018.
  4. Lucchinetti CF, et al. Heterogeneity of inflammatory demyelinating lesions. Brain. 2000.
  5. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018.
  6. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica spectrum disorders. Lancet Neurol. 2014
  7. Jacob A, Weinshenker BG. An approach to the diagnosis of acute transverse myelitis. Semin Neurol. 2008.
  8. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002.
  9. Frohman EM, Wingerchuk DM. Transverse myelitis. N Engl J Med. 2010.
  10. Pardo CA. Neurological complications of COVID-19. Lancet Neurol. 2021.
  11. World Health Organization. Global Advisory Committee on Vaccine Safety reports on COVID-19 vaccines.
  12. Patone M, et al. Neurological complications after SARS-CoV-2 infection and vaccination. Nat Med. 2022.
  13. Li X, et al. Association between COVID-19 vaccination, SARS-CoV-2 infection, and risk of neurological outcomes. Nat Med. 2022.
  14. Maramattom BV, et al. Transverse myelitis following COVID-19 vaccination: case reports and literature review. J Neuroimmunol. 2022.
  15. Wingerchuk DM. Transverse myelitis. Continuum. 2023.
  16. Lucchinetti CF, et al. Inflammatory demyelinating diseases of the central nervous system. Brain. 2021
  17. .Rose NR. Molecular mimicry and autoimmune disease. Cell Mol Life Sci.
  18. Fujinami RS, Oldstone MBA. Molecular mimicry as a mechanism of autoimmunity. Science.
  19. Goverman JM. Immune tolerance and autoimmunity. Nat Rev Immunol.
  20. Steinman L. Mechanisms of CNS autoimmunity. Nature Reviews Immunology.
  21. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol.
  22. McGinley AM, Edwards SC, Raverdeau M, Mills KHG. Th17 biology in CNS inflammation. Nat Rev Immunol.
  23. Hemmer B, Kerschensteiner M, Korn T. Multiple sclerosis immunology. Nat Rev Immunol.
  24. Lassmann H. Mechanisms of demyelination. Cold Spring Harb Perspect Med.
  25. Lucchinetti CF, et al. Heterogeneity of inflammatory demyelinating lesions. Brain.
  26. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med.
  27. Weinshenker BG, Wingerchuk DM. Neuromyelitis optica spectrum disorders. Mayo Clin Proc.
  28. Cobo-Calvo Á, et al. MOG antibody-associated disease. Lancet Neurol.
  29. Bar-Or A, Li R. B-cell biology in neuroimmunology. Nat Rev Neurol.
  30. Zrzavy T, et al. Microglia in inflammatory CNS disease. Brain.
  31. Dendrou CA, Fugger L, Friese MA. Immunogenetics of autoimmune neurological disease. Nat Rev Immunol.
  32. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002.
  33. Frohman EM, Wingerchuk DM. Transverse myelitis. N Engl J Med. 2010.
  34. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica spectrum disorders. Lancet Neurol. 2014.
  35. Cobo-Calvo Á, et al. MOG antibody-associated disease. Lancet Neurol. 2021.
  36. Thompson AJ, et al. Diagnosis of multiple sclerosis: 2021 revisions. Lancet Neurol. 2021.
  37. Disanto G, et al. Serum neurofilament light chain in neurological disease. Nat Rev Neurol. 2017.
  38. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002.
  39. Frohman EM, Wingerchuk DM. Transverse myelitis. N Engl J Med. 2010.
  40. Krishnan C, et al. Transverse myelitis: pathogenesis, diagnosis and treatment. Front Biosci. 2004.
  41. Weinshenker BG. Inflammatory demyelinating diseases of the central nervous system. Continuum. 2019.
  42. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica spectrum disorders. Lancet Neurol. 2014.
  43. Cobo-Calvo Á, et al. Clinical spectrum and prognosis of MOG antibody-associated disease. Lancet Neurol. 2021.
  44. Patone M, et al. Neurological complications after SARS-CoV-2 infection and vaccination. Nature Medicine. 2022
  45. Transverse Myelitis Consortium Working Group. Diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002.
  46. Frohman EM, Wingerchuk DM. Transverse myelitis. N Engl J Med. 2010.
  47. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica spectrum disorders. Lancet Neurol. 2014.
  48. Cobo-Calvo Á, et al. Clinical spectrum and outcomes of MOG antibody disease. Lancet Neurol. 2021.
  49. Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions. Lancet Neurol. 2018.
  50. Flanagan EP, et al. Myelitis associated with autoimmune disorders. Neurology. 2016.
  51. Pittock SJ, Lucchinetti CF. The pathology of CNS inflammatory demyelinating disease. Neurol Clin. 2011.
  52. Greenberg BM, et al. Efficacy of plasma exchange in severe CNS inflammatory disorders. Neurology.
  53. Weinshenker BG, et al. Plasma exchange for acute attacks in CNS inflammatory disease. Ann Neurol.
  54. Frohman EM, Wingerchuk DM. Transverse myelitis. N Engl J Med. 2010.
  55. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica spectrum disorders. Lancet Neurol. 2014.
  56. Pittock SJ, et al. Eculizumab in aquaporin-4-positive NMOSD. N Engl J Med. 2019.
  57. Bennett JL, et al. Neuromyelitis optica and B-cell targeted therapy. Neurology.
  58. Cobo-Calvo Á, et al. MOG antibody-associated disease. Lancet Neurol. 2021.
  59. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002.
  60. Frohman EM, Wingerchuk DM. Transverse myelitis. N Engl J Med. 2010.
  61. Scott TF, et al. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis. Neurology.
  62. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica spectrum disorders. Lancet Neurol. 2014.
  63. Cobo-Calvo Á, et al. MOG antibody-associated disease: clinical characteristics and outcomes. Lancet Neurol. 2021.
  64. Disanto G, et al. Serum neurofilament light chain in neurological disease. Nat Rev Neurol. 2017.
  65. Patone M, et al. Neurological complications after SARS-CoV-2 infection and vaccination. Nature Medicine. 2022
  66. Frohman EM, Wingerchuk DM. Transverse myelitis. N Engl J Med. 2010.
  67. Lassmann H. Mechanisms of demyelination and tissue repair. Cold Spring Harb Perspect Med. 2018.
  68. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018.
  69. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica spectrum disorders. Lancet Neurol. 2014.
  70. Bennett JL, et al. Neuromyelitis optica and emerging therapies. Neurology.
  71. Disanto G, et al. Serum neurofilament light chain as a biomarker. Nat Rev Neurol. 2017.
  72. Thompson AJ, et al. Diagnosis and management of multiple sclerosis and inflammatory demyelination. Lancet Neurol.
  73. Patone M, et al. Neurological complications after SARS-CoV-2 infection and vaccination. Nature Medicine. 2022.

Leave a Reply

Your email address will not be published. Required fields are marked *